Bavarian Nordic (NASDAQ: BVNKY) Gains Swissmedic Nod for Chikungunya Vaccine

April 16, 2026

Key Developments Bavarian Nordic (NASDAQ: BVNKY) has secured approval from Swissmedic, the Swiss Agency for Therapeutic Products, for its chikungunya vaccine, VIMKUNYA®. This authorization allows the vaccine to be used for active immunization to protect individuals aged 12 and older against chikungunya virus infection. This regulatory milestone marks a significant advancement for Bavarian Nordic (NASDAQ: BVNKY) as it expands the availability of its recombinant, adsorbed vaccine to an important European…

Read More >>

Bavarian Nordic (NASDAQ: BVNKF) Swiss Approval for Chikungunya Vaccine

April 16, 2026

Key Developments Bavarian Nordic (NASDAQ: BVNKF) announced a significant regulatory milestone with the Swiss Agency for Therapeutic Products (Swissmedic) granting approval for its chikungunya vaccine, VIMKUNYA®. This vaccine is intended for active immunization against chikungunya virus in individuals aged 12 years and older. The approval from Swissmedic marks a crucial expansion of the vaccine’s availability, underscoring Bavarian Nordic’s advancement in infectious disease prophylaxis. VIMKUNYA® is a recombinant, adsorbed vaccine aimed…

Read More >>